Literature DB >> 25331263

TERT promoter mutations in clear cell renal cell carcinoma.

Ismail Hosen1, P Sivaramakrishna Rachakonda, Barbara Heidenreich, Raviprakash T Sitaram, Börje Ljungberg, Göran Roos, Kari Hemminki, Rajiv Kumar.   

Abstract

We screened promoter region of the telomerase reverse transcriptase (TERT) for activating somatic mutations in 188 tumors from patients with clear cell renal cell carcinoma (ccRCC). Twelve tumors (6.4%) carried a mutation within the core promoter region of the gene. The mutations were less frequent in high grade tumors compared to low grade tumors [odds ratio (OR) = 0.15, 95% confidence interval (CI) = 0.03-0.72, p = 0.02]. Multivariate analysis for cause specific survival showed statistically significant poor outcome in patients with TERT promoter mutations [hazard ratio (HR) = 2.90, 95% CI = 1.13-7.39, p = 0.03]. A common polymorphism (rs2853669) within the locus seemed to act as a modifier of the effect of the mutations on patient survival as the noncarriers of the variant allele with the TERT promoter mutations showed worst survival (HR = 3.34, 95% CI = 1.24-8.98, p = 0.02). We also measured relative telomere length (RTL) in tumors and difference between tumors with and without the TERT promoter mutations was not statistically significant. Similarly, no difference in patient survival based on RTL in tumors was observed. Our study showed a relatively low frequency of TERT promoter mutations in ccRCC. Nevertheless, patients with the mutations, particularly in the absence of the rs2853669 variant showed the worst disease-specific survival. Thus, it is possible that the TERT promoter mutations define a small subset of tumors with an aggressive behavior.
© 2014 UICC.

Entities:  

Keywords:  TERT promoter mutations; mutations; survival; telomere length

Mesh:

Substances:

Year:  2014        PMID: 25331263     DOI: 10.1002/ijc.29279

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.

Authors:  Cristina Pellegrini; Maria Giovanna Maturo; Claudia Martorelli; Mariano Suppa; Ambra Antonini; Dimitra Kostaki; Lucilla Verna; Maria Teresa Landi; Ketty Peris; Maria Concetta Fargnoli
Journal:  Melanoma Res       Date:  2017-06       Impact factor: 3.599

2.  Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

Authors:  Jozefina Casuscelli; Maria F Becerra; Brandon J Manley; Emily C Zabor; Ed Reznik; Almedina Redzematovic; Maria E Arcila; Daniel M Tennenbaum; Mazyar Ghanaat; Mahyar Kashan; Christian G Stief; Maria Carlo; Martin H Voss; Darren R Feldman; Robert J Motzer; Yingbei Chen; Victor E Reuter; Jonathan A Coleman; Paul Russo; James J Hsieh; Abraham Ari Hakimi
Journal:  Eur Urol Focus       Date:  2017-09-24

3.  The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.

Authors:  Z Chen; J Wang; Y Bai; S Wang; X Yin; J Xiang; X Li; M He; X Zhang; T Wu; P Xu; H Guo
Journal:  Cancer Gene Ther       Date:  2016-12-16       Impact factor: 5.987

Review 4.  Oncometabolites in renal cancer.

Authors:  Cissy Yong; Grant D Stewart; Christian Frezza
Journal:  Nat Rev Nephrol       Date:  2019-10-21       Impact factor: 28.314

5.  TERT promoter mutations in melanoma survival.

Authors:  Eduardo Nagore; Barbara Heidenreich; Sívaramakrishna Rachakonda; Zaida Garcia-Casado; Celia Requena; Virtudes Soriano; Christoph Frank; Victor Traves; Esther Quecedo; Josefa Sanjuan-Gimenez; Kari Hemminki; Maria Teresa Landi; Rajiv Kumar
Journal:  Int J Cancer       Date:  2016-03-02       Impact factor: 7.396

6.  Hotspot TERT promoter mutations are rare events in testicular germ cell tumors.

Authors:  Flavio Mavignier Cárcano; Daniel Onofre Vidal; André van Helvoort Lengert; Cristovam Scapulatempo Neto; Luisa Queiroz; Herlander Marques; Fátima Baltazar; Camila Maria da Silva Martinelli; Paula Soares; Eduardo Caetano Albino da Silva; Luiz Fernando Lopes; Rui Manuel Reis
Journal:  Tumour Biol       Date:  2015-11-03

7.  Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.

Authors:  Salvatore Piscuoglio; Charlotte Ky Ng; Melissa Murray; Kathleen A Burke; Marcia Edelweiss; Felipe C Geyer; Gabriel S Macedo; Akiko Inagaki; Anastasios D Papanastasiou; Luciano G Martelotto; Caterina Marchio; Raymond S Lim; Rafael A Ioris; Pooja K Nahar; Ino De Bruijn; Lillian Smyth; Muzaffar Akram; Dara Ross; John H Petrini; Larry Norton; David B Solit; Jose Baselga; Edi Brogi; Marc Ladanyi; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2016-01-25       Impact factor: 7.996

Review 8.  Somatic genetic rescue in Mendelian haematopoietic diseases.

Authors:  Patrick Revy; Caroline Kannengiesser; Alain Fischer
Journal:  Nat Rev Genet       Date:  2019-06-11       Impact factor: 53.242

9.  Mutation rate estimation for 15 autosomal STR loci in a large population from Mainland China.

Authors:  Zhuo Zhao; Jie Zhang; Hua Wang; Zhi-Peng Liu; Ming Liu; Yuan Zhang; Li Sun; Hui Zhang
Journal:  Meta Gene       Date:  2015-07-26

10.  The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.

Authors:  Eunkyong Ko; Hyun-Wook Seo; Eun Sun Jung; Baek-hui Kim; Guhung Jung
Journal:  Oncotarget       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.